주요메뉴 바로가기 본문 바로가기

주메뉴

IBS Conferences

Novel Technology for Anticancer Drug Delivery On Demand

- Light-responsive vesicles carry and release drugs to cancer cells at specific time and position -

With the goal of minimizing the side effects of chemotherapy on healthy tissues, a team of researchers at the Center for Self-assembly and Complexity, within the Institute for Basic Science (IBS) have developed novel nanocontainers able to deliver anticancer drugs at precise timing and location. Published in Angewandte Chemie International Edition, the study combines uniquely designed molecules and light-dependent drug release, which may provide a new platform to enhance the effect of anticancer therapeutics.

Thanks to a serendipitous observation, IBS researchers at POSTECH found out that tailed pumpkin-shaped molecules, mono-allyloxylated cucurbit[7]uril (AO1CB[7]), act as surfactant in water. Most surfactants, like soap molecules in bubbles and phospholipids in cellular membranes, have small water-loving (hydrophilic) heads and long fat-loving (hydrophobic) tails that determine how they arrange in space. In contrast, AO1CB[7] is rather unconventional as it forms vesicles in water despite its short hydrophobic allyloxy tail. Detailed analysis showed that the tails unite AO1CB[7] molecules into colloidal particles.

“Seeing AO1CB[7] forming a cloudy solution when shaken in water was an unexpected surprise for the team,” explains PARK Kyeng Min, the first and corresponding author of the study. “We thought to take advantage of this newly discovered property and use these vesicles as vehicles to carry anticancer drugs. Then, by controlling when and where the vesicles are broken, the drugs could be released on demand.”


Figure 1: Overview of the experiment. Hollow pumpkin-shaped molecules with allyloxy tails self-assemble into vesicles which can carry drugs into cancer cells. Then a laser breaks the vesicles which facilitates the release of the drug in a timely and location-specific manner.


Figure 2: Chemical structure and surfactant features of mono-allyloxylated cucurbit[7]uril (AO1CB[7]). A) and B) show the chemical structure of the AO1CB[7] molecule. C) After vigorous shaking of AO1CB[7] in water, the solution becomes cloudy and foam forms on top, meaning that AO1CB[7] behaves like a surfactant.

Beyond helping AO1CB[7] to self-assemble, the allyloxy tail is also light-responsive: it can react with molecules such as glutathione normally present in cells when irradiated by UV light (365 nanometer wavelength). Similarly to a soap bubble popping, the reaction between the tails and glutathione molecules breaks the AO1CB[7] vesicles apart.

Rather than using UV single-photon laser to promote the glutathione-allyloxy tail reaction, IBS researchers employed a near infrared two-photon laser, which has the ability to penetrate deeper into tissues with increased accuracy. In simple terms, the two-photon laser (wavelength 720 nanometers) is a better tool to use than a single-photon laser (365 nanometers) as it can reach deeper inside flesh with less scattering. As the irradiated area is smaller, the drug delivery is confined to the targeted area, resulting in less damage to healthy tissue surrounding the tumor.

The research team applied this technology to deliver the chemotherapeutic drug Doxorubicin to cervical cancer cells (HeLa cells) in the laboratory. They observed that the drug was able to exit the vesicles, reach the nucleus of the cancer cells, and eventually kill them.


Figure 3: Fluorescent microscopy images of anticancer drug delivery via AO1CB[7] vesicles and two-photon near infra-red laser. The chemotherapeutic drug Doxorubicin (Dox, in red) was entrapped in AO1CB[7] vesicles and delivered to cervical cancer cells (HeLa cells). The image compares the location of Dox in the absence A) and presence B) of infra-red two-photon laser irradiation. In B) the drug is visible inside the nucleus (stained in blue), meaning that the vesicles were disrupted and the drug was able to reach the nucleus, where it fights the cancerous tumor with increased efficiency.

“These cell-level studies represent a proof-of-concept demonstration. Now we want to extend this technology to animal models, such as cancer bearing mice, to verify its practical use in different types of tumors,” explains Park.

Letizia Diamante

Notes for editors

- References
- Kyeng Min Park, Kangkyun Baek, Young Ho Ko, Annadka Shrinidhi, James Murray, Won Hyuk Jang, Ki Hean Kim, Jun-Seok Lee, Jejoong Yoo, Sungwan Kim, and Kimoon Kim. Mono‐allyloxylated Cucurbit[7]uril Acts as an Unconventional Amphiphile to Form Light‐responsive Vesicles. Angewandte Chemie International Edition (2018). DOI: 10.1002/ange.201713059

- Media Contact
For further information or to request media assistance, please contact: Mr. Kyungyoon Min, Head of Communications Team, Institute for Basic Science (IBS) (+82-42-878-8156, kymin@ibs.re.kr);or Ms. Carol Kim, Global Officer, Communications Team, IBS (+82-42-878-8133, clitie620@ibs.re.kr)

- About the Institute for Basic Science (IBS)
IBS was founded in 2011 by the government of the Republic of Korea with the sole purpose of driving forward the development of basic science in South Korea. IBS has launched 28 research centers as of March 2018. There are nine physics, one mathematics, six chemistry, eight life science, one earth science, and three interdisciplinary research centers.

Center for Self-assembly and Complexity

Publication Repository
박경민
Park, Kyeng Min 이메일 보내기 Center for Self-assembly and Complexity Publications
김기문
Kim, Ki Moon 이메일 보내기 Center for Self-assembly and Complexity Publications
  • [Asian Scientist] Precision Drug Release With Pumpkin-Shaped Molecules
  • [Post Online Media] Novel technology for anticancer drug delivery on demand
  • [Photonics Online] Novel Technology For Anticancer Drug Delivery On Demand
  • [Nanowerk News] Novel nanocontainers for anticancer drug delivery on demand
  • [In-Pharma Technologist] Anticancer delivery tech to reduce tissue damage an 'unexpected surprise'
  • [Physics News] Novel technology for anticancer drug delivery on demand
  • [Science Newsline] Novel Technology for Anticancer Drug Delivery on Demand
  • [ScienceDaily] Novel technology for anticancer drug delivery on demand
  • [NEWS FLASH] Novel technology for anticancer drug delivery on demand
  • Research

    Are you satisfied with the information on this page?

    Content Manager
    Communications Team :   042-878-8172
    Last Update 2018-06-25 14:03